Paperonium

Breast cancer · BMC Med · 2026

The summary reports no severe hand-foot skin reactions. The paper’s own table: 5 of 26 patients.

Severe (grade 3)noneThe summary5 of 26Its own table: 19.2%too lowSchedule picked for next phase: severe27.3%3 of 11Any severity50%Its own table: 13 of 260%204060
Severe (grade 3)noneThe summary5 of 26Its own table: 19.2%too lowSchedule picked for next phase: severe27.3%3 of 11Any severity50%Its own table: 13 of 260%204060

Share of patients with hand-foot syndrome; severe means grade 3, the top level

The paper says

26 breast-cancer patients took two drugs, one in tiny fat bubbles meant to shield heart and skin. The summary reports no severe heart damage or hand-foot syndrome (a painful skin reaction on palms and soles); the paper says this early result supports the shielding idea.

Its own data show

The paper’s own table and results: 13 of 26 patients (50%) had hand-foot syndrome, and 5 (19.2%) had grade 3, the most severe level on the standard grading scale the paper uses. On the every-4-weeks schedule the paper recommends for the next phase of trials, 7 of 11 had it, 3 severely.

A paper’s summary is the short overview at the top; many readers, and many databases that index studies, read nothing else. This one contradicts the paper’s own table on a side effect that hit half the patients, and the paper cites that supposed absence as support for the bubbles sparing the skin. Nothing in the paper contradicts the heart claim.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study · BMC Med (2026) · doi:10.1186/s12916-026-04895-9